Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ADAM10, a member of the disintegrin and metalloprotease (ADAM) family, was isolated and purified from the brain myelin of cattle. It was called mammalian integrin metalloprotein, and it was later found to be Cytoplasmic myelin alkaline protease.
ADAM10 belongs to the zinc protease family and is a 750 amino acid type I integrated transmembrane protein composed of multiple functional domains, including prodomain, metalloproteinase domain, de-integration domain, cysteine-rich region, epidermal growth factor like domain, transmembrane domain, and cytoplasmic tail. After excision of the signal sequence, the process by which ADAM10 is activated by two precursor protein invertases, Flyin or Proprotein convertase (PC) 7. This process is called prodomain structural processing.
Figure 1. ADAM10 involvement in Alzheimer disease. (Saftig, et al. 2015)
ADAM10 and Alzheimer's Disease (AD)
The metalloproteinase domain of ADAM10 contains a typical zinc-binding co-recognition motif (HEXGHXXGXXHD). After introducing a point mutation (E384A) in this motif, it was found that APPsα secretion was significantly reduced in HEK cells and mice.
Subsequent studies showed that ADAM10 was expressed in both human brain and peripheral tissues; whereas in ADK293 cells overexpressing ADAM10 cDNA, ADAM10 was first confirmed to have APP-cleaving alpha-secretase activity. Postina et al. crossed Alzheimer disease (AD) mice with ADAM10 transgenic mice and found that the amyloid plaques in the brain of mice were significantly reduced, while the soluble fragment APPsα produced by α-secretase cleavage amyloid precursor protein (APP) increased, and the learning and memory ability of hybrid mice increased. In contrast, ADAM10 mutant mice had reduced APPsα, increased amyloid plaques, and reduced learning ability. The above results indicate that ADAM10 is a functional secretase that inhibits the formation of amyloid plaques by processing APP.
Current studies have shown that activation or overexpression of ADAM10 in the brain is helpful in the treatment of neurodegenerative diseases, especially AD. Studies have found that ADAM10 can significantly improve the emotional activity and exercise capacity of AD mice, reducing learning and cognitive impairment; while ADAM10 overexpressing mice have increased cortical synapse formation. Another study showed that ADAM10 overexpression reduced the symptoms of long-term augmentation disorders in AD model mice and enhanced its learning and memory ability.
Studies have shown that inhibition of ADAM10 expression in mouse neural progenitor cells can lead to perinatal fatal injury, as well as abnormalities in the notch signaling pathway, resulting in immature neuronal differentiation and leading to destruction of the mouse cortex. This suggests that ADAM10 plays an important role in the formation of the cerebral cortex. Notch is a cell surface receptor involved in cell differentiation and is essential for cell growth and development. Studies have shown that ADAM10 plays an important role in the development of B cells by activating the notch signaling pathway.
ADAM10 and Diabetic Encephalopathy (DE)
Diabetic encephalopathy (DE) is a central nervous system damage caused by diabetes and can cause cognitive dysfunction. AD-like changes such as Aβ aggregation caused by DE may be the mechanism for the development of DE.
ADAM10 mediates synaptic development and is closely related to the morphology of synapses. ADAM10 participates in the regulation of cognitive function through regulation of synapses. ADAM10 controls different exfoliated cell adhesion molecules (CAMS) at the postsynaptic site to promote synaptic development and progression. The soluble fragment sAPPα produced by ADAM10 cleavage APP can also participate in synapse formation. In ADAM10 knockout neurons, N-Cadherin and neuroligin-1 are impaired and Aβ produces a large number of damaging synapses, producing short, thick spinous processes that degrade synaptic function and causing cognitive decline. Therefore, how to enhance the hydrolysis activity of ADAM10 in the body, let ADAM10 cleave more APP and produce more sAPPα, and inhibit the formation of amyloid plaque, has become a new direction of research DE.
ADAM10 and Cancer
ADAM10 is overexpressed in oral squamous cell carcinoma and gastric cancer, and antisense oligonucleotides or anti-ADAM10 antibodies reduce its overexpression in cancer cells. It has been reported that ADAM10-mediated human papillomavirus L1 protein can increase cell invasion and metastasis of uterine and ovarian tumors. Human papillomavirus L1 protein also has invasion and metastasis activity in lymphoma, lung cancer and melanoma, and ADAM10 appears to be a major factor in the release of human papillomavirus L1 protein in these tumors. ADAM10 is also expressed in prostate cancer and leukemia.
Abdominal aortic aneurysm (AAA) is a degenerative disease characterized by destruction of the abdominal aortic wall structure and progressive expansion into a pulsatile mass. The study found that ADAM10 can catalyze the release of TNF-α, a key enzyme that promotes chronic inflammation. Not only that, ADAM10 can activate IL-6R, chemokine-like ligand 1 (CX3CL1), CXCL16, VEGFR2, E-cadherin and other membrane-protein molecules that are widely expressed on the surface of vascular system cells participate in the inflammatory response of the arterial wall, and chronic inflammation is exactly one of the important mechanisms of AAA formation.
In addition, ADAM10 is able to separate components between the extracellular matrix and the cell wall, such as collagen IV and colloid, thereby degrading the extracellular matrix component. Studies have shown that ADAM10 may also act on several other extracellular matrix proteins such as cadherin and collagen XVII. The ADAM10 found in human AAA tissue membrane microvesicles has the function of hydrolyzing proteins, which also confirms its involvement in the pathogenesis of AAA.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.